

# Gary Cook

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6574373/publications.pdf>

Version: 2024-02-01

211  
papers

11,966  
citations

34105

52  
h-index

30087

103  
g-index

215  
all docs

215  
docs citations

215  
times ranked

13555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging of Bone Metastases in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 531-541.	4.6	3
2	Radiomic Analysis of Tumour Heterogeneity Using MRI in Head and Neck Cancer Following Chemoradiotherapy: A Feasibility Study. <i>Frontiers in Oncology</i> , 2022, 12, 784693.	2.8	2
3	Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT. <i>Insights Into Imaging</i> , 2022, 13, .	3.4	4
4	<sup>18</sup> F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	7.3	14
5	Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2558-2565.	6.4	13
6	18F-FDG PET-CT and 18F-NaF in Treatment Response Evaluation: Bone Metastases and Bone Tumours. , 2021, , 403-417.		0
7	A Multi-Channel Uncertainty-Aware Multi-Resolution Network for MR to CT Synthesis. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1667.	2.5	7
8	Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis. <i>European Radiology</i> , 2021, 31, 7969-7983.	4.5	14
9	Correlations between DWâ€MRI and 18 Fâ€FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemoâ€radiotherapy. <i>Cancer Reports</i> , 2021, 4, e1360.	1.4	4
10	Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. <i>EJNMMI Physics</i> , 2021, 8, 52.	2.7	8
11	Optimisation of CT protocols in PET-CT across different scanner models using different automatic exposure control methods and iterative reconstruction algorithms. <i>EJNMMI Physics</i> , 2021, 8, 58.	2.7	3
12	An overview of nuclear medicine research in the UK and the landscape for clinical adoption. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 1301-1312.	1.1	0
13	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6457-6466.	7.0	11
14	Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100106.	0.1	2
15	Preclinical development and characterisation of Tc-NM-01 for SPECT/CT imaging of human PD-L1. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 154-166.	1.0	1
16	[18F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging. <i>Tomography</i> , 2021, 7, 843-854.	1.8	8
17	Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data. <i>Cancer Informatics</i> , 2021, 20, 117693512110562.	1.9	2
18	Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 23.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 16-17.	6.4	1
20	Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 759-767.	6.4	28
21	Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence. <i>British Journal of Radiology</i> , 2020, 93, 20190496.	2.2	19
22	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. <i>Radiotherapy and Oncology</i> , 2020, 144, 72-78.	0.6	35
23	The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 674-686.	6.4	29
24	The Role of PET-CT Imaging in Prostate Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 373-391.	1.5	1
25	A Role for FDG PET Radiomics in Personalized Medicine?. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 532-540.	4.6	12
26	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	7.3	1,869
27	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2971-2980.	1.6	61
28	Introduction to Radiomics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 488-495.	5.0	673
29	Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 316-324.	0.8	50
30	Imaging with radiolabelled bisphosphonates. <i>Bone</i> , 2020, 137, 115372.	2.9	9
31	Molecular Imaging of Bone Metastases and Their Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 799-806.	5.0	37
32	Nuclear Medicine Imaging Techniques of the Musculoskeletal System. , 2020, , 381-430.		1
33	Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of <sup>18</sup> F-Fluoride Metabolic Flux Than with Measurement of <sup>18</sup> F-Fluoride PET/CT SUV?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 322-327.	5.0	23
34	Radiomics in esophageal and gastric cancer. <i>Abdominal Radiology</i> , 2019, 44, 2048-2058.	2.1	59
35	PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer. <i>BJU International</i> , 2019, 124, 357-358.	2.5	3
36	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1985151.	3.6	4

#	ARTICLE	IF	CITATIONS
37	Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features. <i>British Journal of Radiology</i> , 2019, 92, 20190159.	2.2	32
38	What can artificial intelligence teach us about the molecular mechanisms underlying disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2715-2721.	6.4	15
39	Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2019, 115, 46-52.	2.6	19
40	Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer. <i>European Radiology</i> , 2019, 29, 5227-5235.	4.5	27
41	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1478-1484.	6.4	17
42	Early Phase I Study of a <sup>99m</sup> Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1213-1220.	5.0	111
43	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.6	15
44	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. <i>BMC Medical Imaging</i> , 2019, 19, 90.	2.7	9
45	UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging. <i>Nuclear Medicine Communications</i> , 2019, 40, 662-674.	1.1	6
46	Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. <i>Nuclear Medicine Communications</i> , 2019, 40, 611-617.	1.1	7
47	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 455-466.	6.4	59
48	Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET?. <i>Molecular Imaging and Biology</i> , 2019, 21, 781-789.	2.6	11
49	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F]fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 821-830.	6.4	31
50	The role of new PET tracers for lung cancer. <i>Minerva Pneumologica</i> , 2019, 58, .	1.6	0
51	Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with <sup>18</sup> F-Fluoride. <i>Journal of Nuclear Medicine</i> , 2019, 60, 569.1-569.	5.0	4
52	Functional and Hybrid Imaging of Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 961-972.	2.8	18
53	Imaging $\alpha$ v $\beta$ 3 integrin expression in skeletal metastases with <sup>99m</sup> Tc-maraciclalide single-photon emission computed tomography: detection and therapy response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 898-903.	6.4	9
54	Challenges and Promises of PET Radiomics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1083-1089.	0.8	121

#	ARTICLE	IF	CITATIONS
55	Imaging of Tumour Heterogeneity: Functional MR Techniques in Oncology. , 2018, , 131-150.		0
56	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. Critical Reviews in Oncology/Hematology, 2018, 124, 66-72.	4.4	43
57	Thyroid Paraganglioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 416-423.	1.3	17
58	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	2.2	70
59	Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 1197-1206.	1.1	13
60	Multitracer Guided PET Image Reconstruction. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 499-509.	3.7	13
61	Measuring validity of response assessment in bone predominant metastatic breast cancer based on clinico-radiological evaluation: An Inter-observer study.. Journal of Clinical Oncology, 2018, 36, e13055-e13055.	1.6	1
62	One Coin, No Need to Flip: Shared PET Targets in Cancer and Coronary Artery Disease. American Journal of Roentgenology, 2017, 208, 434-445.	2.2	0
63	<sup>18</sup> F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 1666-1671.	5.0	55
64	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. Radiology, 2017, 284, 552-561.	7.3	66
65	Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. Translational Oncology, 2017, 10, 459-467.	3.7	2
66	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated <sup>18</sup> F-Fluorodeoxyglucose ( <sup>18</sup> F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer, 2017, 17, 392.	2.6	14
67	The effect of post-injection <sup>18</sup> F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. EJNMMI Research, 2017, 7, 35.	2.5	16
68	Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of <sup>18</sup> F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1845-1852.	6.4	21
69	Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using <sup>18</sup> F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. Journal of Nuclear Medicine, 2017, 58, 891-898.	5.0	91
70	New horizons in multimodality molecular imaging and novel radiotracers. Clinical Medicine, 2017, 17, 444-448.	1.9	3
71	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
72	[ <sup>18</sup> F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. European Urology, 2017, 71, 926-933.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. <i>BMC Cancer</i> , 2017, 17, 494.	2.6	17
74	The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. <i>EJNMMI Research</i> , 2017, 7, 60.	2.5	50
75	Guided Image Reconstruction for Multi-Tracer PET. , 2017, , .		2
76	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1â€“Deficient Thoracic Cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 1778-1785.	1.6	96
77	Clinical Applications of PET/CT in Oncology. , 2017, , 429-450.		6
78	Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice. <i>Chinese Clinical Oncology</i> , 2017, 6, S11-S11.	1.2	10
79	FDG PET-CT: Need for vigilance in patients treated with bleomycin. <i>Indian Journal of Nuclear Medicine</i> , 2017, 32, 122.	0.3	12
80	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
81	An Incidental Renal Oncocytoma: 18F-Choline PET/MRI. <i>Diagnostics</i> , 2016, 6, 14.	2.6	0
82	Sentinel Lymph Node Biopsy in Pelvic Tumors. <i>Clinical Nuclear Medicine</i> , 2016, 41, e288-e293.	1.3	9
83	Sentinel lymph node biopsy in breast cancer. <i>Nuclear Medicine Communications</i> , 2016, 37, 570-576.	1.1	18
84	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. <i>Clinical Nuclear Medicine</i> , 2016, 41, e44-e50.	1.3	30
85	PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. <i>PET Clinics</i> , 2016, 11, 305-318.	3.0	12
86	Multi-technique imaging of bone metastases: spotlight on PET-CT. <i>Clinical Radiology</i> , 2016, 71, 620-631.	1.1	22
87	A Role for Tumor Volume Assessment in Resectable Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3063-3070.	1.5	15
88	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016, 4, 439-447.	2.1	56
89	Molecular Imaging in the Management of Adrenocortical Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e368-e382.	1.3	23
90	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. <i>Oncologist</i> , 2016, 21, 1502-1508.	3.7	16

#	ARTICLE	IF	CITATIONS
91	Is there a role for PET/CT in the evaluation of primary and secondary hyperparathyroidism?. Nuclear Medicine Communications, 2016, 37, 1-2.	1.1	7
92	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. American Journal of Roentgenology, 2016, 207, 534-543.	2.2	121
93	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Journal of Nuclear Medicine, 2016, 57, 275-335.	5.0	84
94	The role of new PET tracers for lung cancer. Lung Cancer, 2016, 94, 7-14.	2.0	47
95	Positron Emission Tomography/Magnetic Resonance Imaging of Gastrointestinal Cancers. Seminars in Ultrasound, CT and MRI, 2016, 37, 352-357.	1.5	4
96	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	1.2	4
97	Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.. Journal of Clinical Oncology, 2016, 34, 42-42.	1.6	0
98	What is the role of radionuclide sentinel lymph node biopsy and dissection in papillary thyroid cancer?. Nuclear Medicine Communications, 2015, 36, 969-970.	1.1	3
99	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clinical Nuclear Medicine, 2015, 40, e259-e264.	1.3	16
100	The role of 18F-FDG PET/CT in the management of testicular cancers. Nuclear Medicine Communications, 2015, 36, 702-708.	1.1	40
101	Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nuclear Medicine Communications, 2015, 36, 815-818.	1.1	10
102	Imaging Tumor Response and Tumoral Heterogeneity in Non-“Small Cell Lung Cancer Treated With Antiangiogenic Therapy. Journal of Thoracic Imaging, 2015, 30, 300-307.	1.5	12
103	PET/MRI in Oncological Imaging: State of the Art. Diagnostics, 2015, 5, 333-357.	2.6	37
104	Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS ONE, 2015, 10, e0137036.	2.5	139
105	The precision of textural analysis in 18F-FDG-PET scans of oesophageal cancer. European Radiology, 2015, 25, 2805-2812.	4.5	66
106	Non-“Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of <sup>18</sup> F-FDG Uptake at PET-“Association with Treatment Response and Prognosis. Radiology, 2015, 276, 883-893.	7.3	147
107	Molecular imaging of hypoxia in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 956-976.	6.4	50
108	Multimodal Partial-Volume Correction: Application to <sup>18</sup> F-Fluoride PET/CT Bone Metastases Studies. Journal of Nuclear Medicine, 2015, 56, 1408-1414.	5.0	10

#	ARTICLE	IF	CITATIONS
109	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. <i>Clinical Radiology</i> , 2015, 70, 1060-1082.	1.1	54
110	Texture analysis of 125I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. <i>British Journal of Cancer</i> , 2015, 112, 1882-1887.	6.4	19
111	Challenges for imaging and therapy of musculoskeletal tumours. <i>Clinical and Translational Imaging</i> , 2015, 3, 79-81.	2.1	0
112	Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. <i>Insights Into Imaging</i> , 2015, 6, 489-497.	3.4	149
113	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. <i>Ecological Management and Restoration</i> , 2015, 28, 172-179.	0.4	77
114	Multiparametric MRI assessment during cisplatin and trastuzumab therapy in esophageal adenocarcinoma xenografts.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15108-e15108.	1.6	0
115	Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2612-TPS2612.	1.6	0
116	Bone metastases in prostate cancer: which scan?. <i>BJU International</i> , 2014, 114, 792-793.	2.5	0
117	18F-FDG PET Rarely Provides Additional Information to 11C-Methionine PET Imaging in Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2014, 39, 237-242.	1.3	20
118	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 112-128.	2.1	2
119	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 276-282.	6.4	59
120	Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. <i>European Radiology</i> , 2014, 24, 998-1005.	4.5	181
121	Radiomics in PET: principles and applications. <i>Clinical and Translational Imaging</i> , 2014, 2, 269-276.	2.1	103
122	Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19124-e19124.	1.6	0
123	Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 317-323.	4.6	30
124	18F-FDG PET/CT in HIV-related central nervous system pathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1420-1427.	6.4	29
125	The isotope bone scan: we can do better. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1139-1140.	6.4	9
126	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320



#	ARTICLE	IF	CITATIONS
127	Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, 112-117.	0.6	39
128	Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 133-140.	6.4	395
129	Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2013, 54, 173-175.	5.0	6
130	Are Pretreatment <sup>18</sup> F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 19-26.	5.0	361
131	Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication. <i>Nuclear Medicine Communications</i> , 2013, 34, 1075-1083.	1.1	14
132	Influence of three reconstruction algorithms on the estimation of the standardized uptake value in <sup>18</sup> F-fluoride PET. , 2013, , .		1
133	Fluorodeoxyglucose positron emission tomography ( <sup>18</sup> F-FDG PET)/computed tomography ( <sup>18</sup> F-FDG PET/CT) in bladder cancer. <i>BJU International</i> , 2013, 112, 709-709.	2.5	1
134	Can 18F-FDG PET/CT Reliably Assess Response to Primary Treatment of Head and Neck Cancer?. <i>Clinical Nuclear Medicine</i> , 2013, 38, 263-265.	1.3	21
135	Comparison of six quantitative methods for the measurement of bone turnover at the hip and lumbar spine using 18F-fluoride PET-CT. <i>Nuclear Medicine Communications</i> , 2012, 33, 597-606.	1.1	18
136	Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. <i>Insights Into Imaging</i> , 2012, 3, 573-589.	3.4	738
137	Functional imaging techniques in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1070-1079.	6.4	16
138	Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. <i>European Radiology</i> , 2012, 22, 1465-1478.	4.5	17
139	Elevated CEA level in the asymptomatic patient with normal conventional imaging: How useful is PET-CT for the detection of colorectal cancer recurrence?. <i>Journal of Clinical Oncology</i> , 2012, 30, 400-400.	1.6	1
140	Lung, Thyroid, Renal Cancer, Myeloma and Neuroendocrine Cancers: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 691-715.		0
141	Bone Scintigraphy in Metabolic Bone Disease. , 2012, , 435-444.		0
142	Primary Bone and Soft Tissue Tumours: Role of 18FDG PET. , 2012, , 777-786.		0
143	Conventional Nuclear Medicine and Hybrid Imaging in Monitoring the Treatment of Skeletal Malignancy. , 2012, , 717-734.		0
144	Corrigendum to "Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer" [Radiother Oncol 97 (2010) 101-107]. <i>Radiotherapy and Oncology</i> , 2011, 98, 285.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Validation of image-derived arterial input functions at the femoral artery using 18F-fluoride positron emission tomography. <i>Nuclear Medicine Communications</i> , 2011, 32, 808-817.	1.1	18
146	Validation of new image-derived arterial input functions at the aorta using 18F-fluoride positron emission tomography. <i>Nuclear Medicine Communications</i> , 2011, 32, 486-495.	1.1	18
147	Positron emission tomography computed tomography in oncology. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2011, 72, 631-637.	0.5	5
148	18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). <i>EJNMMI Research</i> , 2011, 1, 4.	2.5	99
149	The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 7-13.	6.4	54
150	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
151	PET-CT of Esophageal Cancer. , 2011, , 181-191.		0
152	Differences in Skeletal Kinetics Between Vertebral and Humeral Bone Measured by 18F-Fluoride Positron Emission Tomography in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 763-769.	2.8	61
153	Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. <i>Journal of Surgical Oncology</i> , 2010, 101, 486-494.	1.7	33
154	Review article: PET and PET/CT imaging of skeletal metastases. <i>Cancer Imaging</i> , 2010, 10, 153-160.	2.8	39
155	18F-Fluoride PET and PET/CT Imaging of Skeletal Metastases. <i>PET Clinics</i> , 2010, 5, 275-280.	3.0	1
156	Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. <i>Radiotherapy and Oncology</i> , 2010, 97, 101-107.	0.6	42
157	Miscellaneous Indications in Bone Scintigraphy: Metabolic Bone Diseases and Malignant Bone Tumors. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 52-61.	4.6	23
158	Skeletal metastases: what is the future role for nuclear medicine?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1803-1806.	6.4	6
159	Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naïve and treated postmenopausal women. <i>Bone</i> , 2009, 45, 942-948.	2.9	44
160	Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): An update of a planning study. <i>Radiotherapy and Oncology</i> , 2009, 91, 349-352.	0.6	43
161	Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 416-430.	4.6	66
162	Patterns, Variants, Artifacts, and Pitfalls in Conventional Radionuclide Bone Imaging and SPECT/CT. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 380-395.	4.6	99

#	ARTICLE	IF	CITATIONS
163	18F-Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal Cancer. <i>Annals of Surgery</i> , 2009, 250, 247-254.	4.2	59
164	Perioperative use of radioisotopes. <i>Surgery</i> , 2008, 26, 261-268.	0.3	0
165	Ensuring the right PET scan for the right patient. <i>Lung Cancer</i> , 2008, 59, 48-56.	2.0	13
166	Follicular Thyroid Carcinoma Metastasis to the Esophagus Detected by 18FDG PET/CT. <i>Thyroid</i> , 2008, 18, 267-271.	4.5	12
167	Evaluation of the role of <sup>18</sup> F-FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. <i>Acta Oncologica</i> , 2008, 47, 1229-1236.	1.8	28
168	Long-Term Precision of <sup>18</sup> F-Fluoride PET Skeletal Kinetic Studies in the Assessment of Bone Metabolism. <i>Journal of Nuclear Medicine</i> , 2008, 49, 700-707.	5.0	62
169	MRI or Bone Scan or Both for Staging of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5837-5838.	1.6	15
170	A potential to reduce pulmonary toxicity: The use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2007, 83, 156-162.	0.6	76
171	The Relationship Between Regional Bone Turnover Measured Using 18F-fluoride Positron Emission Tomography and Changes in BMD Is Equivalent to That Seen for Biochemical Markers of Bone Turnover. <i>Journal of Clinical Densitometry</i> , 2007, 10, 46-54.	1.2	30
172	Unusual presentation of metastatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 116.	1.9	2
173	Case report: PET/CT, a cautionary tale. <i>BMC Cancer</i> , 2007, 7, 147.	2.6	2
174	Preparation and Use of <sup>131</sup> I Magic Gel as a Dosimeter for Targeted Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 427-436.	1.0	10
175	Neuron-specific enolase expression in multiple myeloma. <i>Lancet Oncology</i> , 2006, 7, 960.	10.7	3
176	Radioisotope and PET Imaging of Bone Metastases. , 2006, , 77-90.		0
177	Positron emission tomography in oncology. <i>British Medical Bulletin</i> , 2006, 79-80, 171-186.	6.9	13
178	Artifacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2006, , 63-77.		1
179	PET Imaging of the Skeleton. , 2006, , 317-335.		2
180	Clinical PET Imaging. , 2005, , 347-364.		0

#	ARTICLE	IF	CITATIONS
181	Metastatic Thyroid Carcinoma Causing Superior Vena Caval Obstruction Diagnosed on I-131 Scan. <i>Clinical Nuclear Medicine</i> , 2005, 30, 548-549.	1.3	3
182	Artefacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2005, , 281-293.		2
183	The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 271-277.	0.6	100
184	Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 1-4.	0.6	54
185	Positron emission tomography and bone metastases. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 135-142.	4.6	218
186	Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2004, 150, 649-653.	3.7	13
187	What's new in â€¦ Positron emission tomography. <i>Medicine</i> , 2004, 32, 1-4.	0.4	0
188	Dissociation Between Global Markers of Bone Formation and Direct Measurement of Spinal Bone Formation in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1797-1804.	2.8	67
189	Issues undermining provision of diagnostic imaging in the UK. <i>Lancet Oncology</i> , The, 2004, 5, 467-468.	10.7	1
190	Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 122-133.	4.6	241
191	Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. <i>Radiotherapy and Oncology</i> , 2004, 73, 277-283.	0.6	63
192	A Prospective Study of Risedronate on Regional Bone Metabolism and Blood Flow at the Lumbar Spine Measured by 18 F-Fluoride Positron Emission Tomography. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2215-2222.	2.8	82
193	New Horizons in Oncologic Imaging. <i>New England Journal of Medicine</i> , 2003, 348, 2487-2488.	27.0	45
194	Positron-emission Tomography Used to Diagnose Tuberculosis in a Renal Transplant Patient. <i>American Journal of Transplantation</i> , 2002, 2, 105-107.	4.7	9
195	Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 28-49.	4.6	254
196	The role of positron emission tomography in skeletal disease. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 50-61.	4.6	94
197	The role of nuclear medicine in monitoring treatment in skeletal malignancy. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 206-211.	4.6	69
198	Dual-modality imaging. <i>European Radiology</i> , 2001, 11, 1857-1858.	4.5	19

#	ARTICLE	IF	CITATIONS
199	The role of positron emission tomography in the management of bone metastases. <i>Cancer</i> , 2000, 88, 2927-2933.	4.1	137
200	Renovascular Disease. <i>Clinical Radiology</i> , 2000, 55, 1-12.	1.1	18
201	Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1424-1429.	6.4	63
202	Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1363-1378.	6.4	228
203	Skeletal metastases from breast cancer: Imaging with nuclear medicine. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 69-79.	4.6	58
204	An Unusual Pathologic Fracture in Metastatic Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 1998, 23, 554.	1.3	0
205	Back pain: Can we make a contribution?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 363-367.	2.1	6
206	Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. <i>CardioVascular and Interventional Radiology</i> , 1997, 20, 314-316.	2.0	7
207	Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. <i>Seminars in Nuclear Medicine</i> , 1996, 26, 308-314.	4.6	358
208	Lateral collateral ligament tear of the knee: appearances on bone scintigraphy with single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 720-722.	2.1	14
209	Comparative assessment of small intestinal and colonic permeability in HIV-infected homosexual men. <i>Aids</i> , 1995, 9, 1009-1016.	2.2	19
210	An evaluation of Technegas as a ventilation agent compared with krypton-81 m in the scintigraphic diagnosis of pulmonary embolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 770-4.	2.1	29
211	Positron Emmision Tomography in Lung Cancer. , 0, , 84-98.		0